APO-CYCLOSPORINE ORAL SOLUTION Canada - English - Health Canada

apo-cyclosporine oral solution

apotex inc - cyclosporine - solution - 100mg - cyclosporine 100mg - immunosuppressive agents

CYCLOSPORINE CAPSULE Canada - English - Health Canada

cyclosporine capsule

sandoz canada incorporated - cyclosporine - capsule - 25mg - cyclosporine 25mg - immunosuppressive agents

EPTIFIBATIDE INJECTION SOLUTION Canada - English - Health Canada

eptifibatide injection solution

teva canada limited - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

EPTIFIBATIDE INJECTION SOLUTION Canada - English - Health Canada

eptifibatide injection solution

teva canada limited - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

EPTIFIBATIDE INJECTION SOLUTION Canada - English - Health Canada

eptifibatide injection solution

accord healthcare inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

EPTIFIBATIDE INJECTION SOLUTION Canada - English - Health Canada

eptifibatide injection solution

accord healthcare inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

TEVA-CYCLOSPORINE EMULSION Canada - English - Health Canada

teva-cyclosporine emulsion

teva canada limited - cyclosporine - emulsion - 0.05% - cyclosporine 0.05% - anti-inflammatory agents, miscellaneous

EPTIFIBATIDE- eptifibatide injection, solution United States - English - NLM (National Library of Medicine)

eptifibatide- eptifibatide injection, solution

teva parenteral medicines, inc. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 2 mg in 1 ml - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke - current o

EPTIFIBATIDE injection United States - English - NLM (National Library of Medicine)

eptifibatide injection

aurobindo pharma limited - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 75 mg in 100 ml

EPTIFIBATIDE injection solution United States - English - NLM (National Library of Medicine)

eptifibatide injection solution

teva parenteral medicines, inc. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 0.75 mg in 1 ml